By Shalini Bhardwaj
New Delhi – October 10
The Central Drugs Standard Control Organisation (CDSCO) is tightening its grip on cough‑syrup factories across India. State officials have already been asked to hand over a complete list of all companies that make cough syrup, so that the agency can schedule inspections, run tests and carry out audits.
India’s recent cough‑syrup scare is still fresh in the public eye. In Madhya Pradesh, a contaminated product called Coldrif has been linked to the deaths of 22 children. The company that makes Coldrif, Sresan Pharmaceuticals, received its first license in 2011 from the state FDA and renewed it in 2016. During a joint inspection, regulators found 38 critical violations—out of 364 total—at the Tamil Nadu‑licensed plant.
The crisis drew international attention. The World Health Organization (WHO) has expressed deep concern and is monitoring the situation closely. WHO stresses it will support Indian authorities in the investigation, especially after reports of high levels of diethylene glycol—a toxic chemical—in the cough syrup sold in Madhya Pradesh. While Rajasthan reported deaths related to acute respiratory syndrome and encephalitis, authorities clarified that those cases were not linked to cough syrup.
CDSCO has also confirmed that none of the implicated cough syrups were exported outside India. The agency is working under the banner of a “robust system” to prevent future incidents and protect public health.
Source: aninews
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
